28 The Active Ulcerative Colitis (ACT) trials showed that induction with intravenous infliximab 5 mg/kg at weeks 0, 2, and 6 followed by scheduled maintenance therapy every 8 weeks is effective in refractory moderate-to-severe ulcerative colitis to improve the disease, to induce remission, to ...